A Deeper Look into the Latest Data in the Treatment of Multiple Sclerosis: Leveraging Recent Evidence to Make Informed Decisions

A continuing medical education activity sponsored by NAMCP and AAMCN.

Optimizing Treatment Regimens, Switching and Sequencing in Multiple Sclerosis: Leveraging Data to Make Informed Decision is a 3-part live webinar series that will provide attendees with
the latest information in the management of Multiple Sclerosis

This is Part 1 of the series focusing on the latest data in the treatment of Multiple Sclerosis

This activity is an archive from the webinar held December 9, 2019

This activity is valid from January 1, 2020 to January 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Biogen and Genzyme Corporation

Description:
Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the US, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. While the explosion of these therapies have shown the ability to improve outcomes and quality of life in patient's MS, it makes staying current with best practices a challenge. This webinar series will allow attendees to be aware of the current treatment landscape as well as the cost implications to best develop a benefits design strategy and treatment plans that can minimize the economic burden and optimize care.

Upon completion of this activity, participants will be able to:

  • Examine the impact of multiple sclerosis (MS) on a patient’s quality of life and the burden to the healthcare system

  • Identify key pathogenic mechanisms identified in multiple sclerosis (MS) and implications for targeted therapies

  • Analyze updated clinical data on the efficacy, safety, and dosing/administration of current and emerging therapies and their effect on staging and sequencing

  • Explore recently updated evidence-based data for the rationale of sequencing, switching, and/or escalating MS therapeutics

  • Implement knowledge about MS therapies and aspects of a patient's presentation to make an informed decision when switching MS therapies
     

Faculty: Fred D. Lublin, M.D., FAAN, FANA
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai

Disclosure:

Dr. Lublin serves as a consultant and advisory board member for Bayer HealthCare, Biogen, EMD Serono, Novartis, Teva, Actelion, Sanofi/Genzyme, Acorda, Roche/Genentech, MedImmune, Receptos/Celgene, Forward Pharma, TG Therapeutics, AbbVie, Regeneron, Medday, Atara Biotherapeutics, Polpharma, Mapi Pharma, Innate Immunotherapeutics, Apitope, Orion Biotechnology, Brainstorm Cell therapeutics, and Immunic. He has received funding for research from Novartis Pharmaceuticals Corp, Teva Neuroscience, Actelion, Transparency Life Sciences, NMSS, and Sanofi. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Biogen and Genzyme Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue